Introduction Type 2 diabetes (T2D) is one of the major health concerns affecting 9% of the global population, putting those affected at risk of cardiovascular-associated mortality ( The incretins glucagon-like peptide-1 (GLP-1) and glucose-stimulated insulinotropic polypeptide (GIP) are peptide hormones secreted from intestinal enteroendocrine cells ( Since 2005, six incretin therapy drugs have been approved by the FDA (United States) and the MHRA (United Kingdom) for T2D treatment: Exenatide, Lixisenatide, Liraglutide, Dulaglutide, Semaglutide and Tirzepatide, all of which are administered daily or once weekly via subcutaneous injection
Pelle MC, Provenzano M, Zaffina I, Pujia R, Giofr F, Luc S, et al
This side effect has not been fun and has been challenging, but I think the benefits have outweighed the cost, she said
Diab Metab Syndr 60:12461257 Jung YA, Choi YK, Jung GS et al (2014) Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis
Potential Reduction in Food Cravings and Binge Eating GLP-1 also assists in reducing food cravings and episodes of binge eating
We have the experience and resources to investigate complex product liability cases and confront the legal teams of multinational drug companies
